title: [Crizotinib: a targeted therapy in advanced ALK-positive non-small cell lung cancer].
abstract: Crizotinib is a small orally-administered ALK inhibitor for patients with non-small cell lung cancer with EML4-ALK rearrangement (echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase). This fusion gene is detected with a break apart fluorescence in situ hybridization (FISH) assay. Phase I to III trials have shown an interesting disease control rate and acceptable tolerability. Crizotinib is available in France under temporary use authorization. New potentially effective therapeutics in ALK-positive NSCLC are being developed.
authors.affiliation: UM Oncologie Thoracique, pôle Cancérologie Médecine Aiguë et Communautaire, Centre Hospitalier Universitaire A.-Michallon, BP 217, 38043 Grenoble cedex 9, France. AToffart@chu-grenoble.fr
authors.forename: A-C
authors.initials: AC
authors.lastname: Toffart
authors.forename: L
authors.initials: L
authors.lastname: Sakhri
authors.forename: D
authors.initials: D
authors.lastname: Moro-Sibilot
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D002986:Clinical Trials as Topic; D000077547:Crizotinib; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000009:adverse effects; D005602:France; D015321:Gene Rearrangement / Q000235:genetics; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational; C501947:EML1-ABL1 fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib